Liquid chalcogenide compositions and methods of manufacturing and using the same
View Patent ↗The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.
1. A sterile, stable aqueous pharmaceutical composition comprising:
a solution of deoxygenated water and sodium sulfide nonahydrate,
wherein the sodium sulfide nonahydrate produces Na 2 S, H 2 S and HS − ,
wherein the concentration of H 2 S is in the range of 1.0 mg/mL to 4.0 mg/mL;
wherein the solution is adjusted to a pH in the range of 7.5 to 8.5 by adding HCI to the solution;
wherein the solution has an osmolarity in the range of 250-330 mOsmol/L;
wherein the solution further comprises sulfide oxidation products selected from the group consisting of polysulfide, sulfite, sulfate and thiosulfate;
wherein the oxidation products comprise sulfate in the range of (0%-1.0%), sulfite in the range of (0%-1.0%), polysulfide in the range of (0%-1%) or thiosulfate in the range of (0%-1.0%);
wherein the solution is isotonic or near isotonic; and,
wherein the solution is stable for at least four months.
2. The composition of claim 1 , wherein said composition has an oxygen content in the range of 0 μM to 5 μM, 0 μM to 3 μM, 0.01 μM to 1 μM, or 0.001 μM to 1 μM.
3. A sterile, stable pharmaceutical composition comprising:
a solution of deoxygenated water and Na 2 S,
wherein the Na 2 S produces HS − ,
wherein the solution has a pH in the range of 7.8 to 8.2;
wherein the solution has an osmolarity in the range of 250-330 mOsmol/L;
wherein the solution further comprises sulfide oxidation products selected from the group consisting of polysulfide, sulfite, sulfate and thiosulfate;
wherein the oxidation products comprise sulfate in the range of (0%-1.0%), sulfite in the range of (0%-1.0%), polysulfide in the range of (0%-1%) or thiosulfate in the range of (0%-1.0%);
wherein the solution is stable for at least four months; and,
wherein the solution is isotonic or near isotonic.
4. A sterile, stable, liquid pharmaceutical composition made by the steps, in any suitable order, comprising:
making a solution of Na 2 S by rinsing Na 2 S.9H 2 O crystals with deoxygenated, distilled and deionized water;
bubbling N 2 , a mixture of N 2 /CO 2 , or a mixture of N 2 /H 2 S through the solution generating the Na 2 S that produces HS − , and,
adjusting the pH of the solution to a pH in the range of 7.5 to 8.5 by adding HCI to the solution;
wherein said solution has an osmolarity in the range of 250-330 mOsmol/L ;
wherein said solution further comprises sulfide oxidation products selected from the group consisting of polysulfide, sulfite, sulfate and thiosulfate;
wherein the oxidation products comprise sulfate in the range of (0%-1.0%), sulfite in the range of (0%-1.0%), polysulfide in the range of (0%-1%) or thiosulfate in the range of (0%-1.0%); and,
wherein said composition is isotonic or near isotonic.
5. The composition of claim 4 , wherein the N 2 is bubbled through the solution.
6. The composition of claim 3 , wherein the concentration of HS − is in the range of 1 mM to 250 mM, 10mM to 200mM or 95mM to 150 mM.
7. The composition of claim 4 , wherein the concentration of HS − is in the range of 1 mM to 250 mM, 10 mM to 200 mM or 95 mM to 150 mM.
8. The composition of claim 1 , wherein the concentration of HS − is in the range of 1 mM to 250 mM, 10mM to 200 mM or 95 mM to 150 mM.